Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Net Cash Flow (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Net Cash Flow data on record, last reported at $70.9 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 189.96% year-over-year to $70.9 million; the TTM value through Dec 2025 reached $88.8 million, up 169.63%, while the annual FY2025 figure was $88.8 million, 169.63% up from the prior year.
  • Net Cash Flow reached $70.9 million in Q4 2025 per TARS's latest filing, up from $16.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $119.9 million in Q3 2023 and bottomed at -$97.8 million in Q4 2022.
  • Average Net Cash Flow over 5 years is $902700.0, with a median of -$3.3 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: skyrocketed 844.6% in 2021, then tumbled 4469.8% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$12.5 million in 2021, then crashed by 684.58% to -$97.8 million in 2022, then skyrocketed by 98.24% to -$1.7 million in 2023, then crashed by 4469.8% to -$78.8 million in 2024, then surged by 189.96% to $70.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $70.9 million in Q4 2025, $16.1 million in Q3 2025, and -$79.1 million in Q2 2025.